07:00 , Jun 13, 2016 |  BioCentury  |  Finance

Venture double-double

With a new CEO who is prioritizing innovation, Merck KGaA is expanding its venture arm for the second time in hopes it will deliver even more deal flow to the corporate business development team. The...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Merck KGaA sales and marketing update

Merck’s Merck Serono S.A. unit launched Early Embryo Viability Assessment (Eeva) test in undisclosed European countries to improve in vitro fertilization outcomes. Eeva is a non-invasive imaging test that provides quantitative information on embryo viability...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Auxogyn, Merck KGaA sales and marketing update

Auxogyn granted Merck's Merck Serono S.A. unit exclusive rights to commercialize Auxogyn's Early Embryo Viability Assessment (Eeva) test in Europe and Canada. Merck also has the option to extend the right to undisclosed countries and...
07:00 , May 20, 2013 |  BioCentury  |  Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Auxogyn, Merck KGaA deal

Merck's Merck Serono S.A. unit partnered with Auxogyn to develop its Early Embryo Viability Assessment (Eeva) Test . Merck Serono will provide strategic, scientific and medical support in the development and commercialization of the test....
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

Early Embryo Viability Assessment regulatory update

Auxogyn said it received CE Mark approval for its Eeva Test to improve in vitro fertilization outcomes. Auxogyn plans to immediately launch the test in the EU. The non-invasive imaging test provides quantitative information on...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Early Embryo Viability Assessment diagnostic data

A study in 160 patients and about 1,800 embryos showed that Auxogyn's Eeva Test predicted blastocyst formation at the cleavage stage with 85% specificity and reduced the false positive rate to 15% from 43% with...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Company News

Auxogyn board of directors update

Auxogyn Inc. , Menlo Park, Calif.   Business: Diagnostic   Appointed: Simeon George, partner at SR One; and Nilesh Kumar, director of Merck Serono Ventures  ...